TABLE 3.

Clinicopathologic characteristics of HHLA2 expression in KIRC patients from the discovery and validation groups.

Parameter	Discovery cohort (n = 90)			Validation cohort 1 (n = 150)			Validation cohort 2 (n = 250)
	HHLA2 Low	HHLA2 High	P	HHLA2 Low	HHLA2 High	P	HHLA2 Low	HHLA2 High	P
Agea (year)			0.800			0.899			0.776
<65	25	34		61	60		92	90
≥65	14	17		15	14		33	35
Gendera			0.966			0.977			0.241
Female	17	22		22	21		52	43
Male	22	29		54	53		73	82
Tumor gradea			0.448			<0.001			0.006
I	15	25		38	22		52	57
II	17	21		19	43		40	53
III	7	5		18	9		30	10
IV	0	0		1	0		4	5
Stagea			0.357			0.305			0.891
I	28	32		61	61		96	98
II	7	11		7	9		16	18
III	3	1		7	4		8	6
IV	0	2		1	0		3	2
Unknown	1	5		0	0		2	1
Overall survivalb (months)	63.94	84.22	0.014	63.63	73.10	0.039	34.50	39.76	<0.001

^aχ² test; ^bStudent’s t-test.